Understanding the role of bilevel positive airway pressure (BPAP) in pediatric acute asthma exacerbations: A prospective, randomized, double blind, controlled trial.

哮喘仍然是美国儿童住院的三大原因之一。干预措施 迅速逆转支气管梗阻并减少对持续β-受体激动剂治疗的需求不仅将 直接惠及患者，也减少了急诊护理资源的消耗。双水平正压气道 压力(BPAP)是一种无创的正压通气，可以支架开放的呼吸道，改善 清除粘液，补充肺泡，增加对持续β-激动剂治疗的反应性 远端呼吸道。然而，BPAP目前不是NIH儿童急性呼吸窘迫综合征治疗指南的一部分 继发性哮喘是由于缺乏高质量的儿科临床试验。这种前瞻性、随机性、双重化的目标 一项盲法对照试验旨在确定早期开始BPAP对出现以下症状的儿科患者是否有效和安全 到急诊科的儿童急诊科，有中到重度哮喘急性加重，但未能通过第一线 心理治疗。

Asthma remains one of the top three causes of hospitalization in children in the United States. Interventions that rapidly reverse bronchial obstruction and decrease the need for continuous beta-agonist therapy will not only directly benefit the patient, but also decrease the consumption of acute care resources. Bilevel positive airway pressure (BPAP) is a form of non-invasive positive pressure ventilation that may stent open airways, improve mucous clearance, recruit alveoli, and increase responsiveness to continuous beta-agonist therapy in the small distal airways. However, BPAP is not currently part of the NIH guidelines for the management of pediatric acute asthma secondary to the lack of quality pediatric clinical trials. The goal of this prospective, randomized, double blind, controlled trial is to determine if early initiation of BPAP is effective and safe in pediatric patients presenting to a pediatric emergency department with acute moderate to severe asthma exacerbations who fail first line therapy.